The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
4-chloro-N-(2,2-dichloro-1-{[(E)-(cyanoimino)(pyridin-3-ylamino)methyl]amino}propyl)benzamide ID: ALA239512
PubChem CID: 44436328
Max Phase: Preclinical
Molecular Formula: C17H15Cl3N6O
Molecular Weight: 425.71
Molecule Type: Small molecule
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: CC(Cl)(Cl)[C@@H](NC(=O)c1ccc(Cl)cc1)N/C(=N/C#N)Nc1cccnc1
Standard InChI: InChI=1S/C17H15Cl3N6O/c1-17(19,20)15(25-14(27)11-4-6-12(18)7-5-11)26-16(23-10-21)24-13-3-2-8-22-9-13/h2-9,15H,1H3,(H,25,27)(H2,23,24,26)/t15-/m0/s1
Standard InChI Key: VWXQCJYCNKGDEL-HNNXBMFYSA-N
Molfile:
RDKit 2D
27 28 0 0 1 0 0 0 0 0999 V2000
3.6861 0.8084 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.6849 -0.0190 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.3997 -0.4319 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
5.1162 -0.0185 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.1133 0.8120 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.3979 1.2211 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.8262 1.2272 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
6.5422 0.8174 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.2552 1.2326 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
6.5454 -0.0076 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
5.8324 -0.4228 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.1125 -0.8292 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
7.9712 0.8228 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.6841 1.2380 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
7.9743 -0.0022 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.9667 -0.8250 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.7993 -0.0045 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
7.1493 -0.0022 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
9.4001 0.8282 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.1130 1.2433 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.4032 0.0032 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
10.8262 0.8314 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.5386 1.2459 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.5359 2.0718 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.8149 2.4814 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.1054 2.0645 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.2483 2.4879 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
13 14 1 0
5 7 1 0
13 15 1 6
3 4 2 0
15 16 1 0
7 8 1 0
15 17 1 0
15 18 1 0
8 9 1 0
14 19 1 0
4 5 1 0
19 20 1 0
8 10 2 0
19 21 2 0
2 3 1 0
20 22 2 0
10 11 1 0
22 23 1 0
5 6 2 0
23 24 2 0
11 12 3 0
24 25 1 0
6 1 1 0
25 26 2 0
26 20 1 0
9 13 1 0
24 27 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 425.71Molecular Weight (Monoisotopic): 424.0373AlogP: 3.52#Rotatable Bonds: 5Polar Surface Area: 102.20Molecular Species: NEUTRALHBA: 4HBD: 3#RO5 Violations: ┄HBA (Lipinski): 7HBD (Lipinski): 3#RO5 Violations (Lipinski): ┄CX Acidic pKa: ┄CX Basic pKa: 1.89CX LogP: 3.60CX LogD: 3.60Aromatic Rings: 2Heavy Atoms: 27QED Weighted: 0.22Np Likeness Score: -1.53
References 1. Perez-Medrano A, Buckner SA, Coghlan MJ, Gregg RJ, Gopalakrishnan M, Kort ME, Lynch JK, Scott VE, Sullivan JP, Whiteaker KL, Carroll WA.. (2004) Design and synthesis of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder., 14 (2): [PMID:14698167 ] [10.1016/j.bmcl.2003.10.063 ] 2. Perez-Medrano A, Brune ME, Buckner SA, Coghlan MJ, Fey TA, Gopalakrishnan M, Gregg RJ, Kort ME, Scott VE, Sullivan JP, Whiteaker KL, Carroll WA.. (2007) Structure-activity studies of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder., 50 (24): [PMID:17973362 ] [10.1021/jm7010194 ]